Sean Laaman
Stock Analyst at Morgan Stanley
(4.38)
# 650
Out of 5,182 analysts
27
Total ratings
68.18%
Success rate
15.3%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GENB Generate Biomedicines | Initiates: Overweight | $20 | $14.46 | +38.31% | 1 | Mar 24, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Overweight | $32 | $10.27 | +211.59% | 1 | Mar 2, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $96 → $98 | $68.99 | +42.05% | 2 | Feb 25, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $48 → $49 | $44.17 | +10.94% | 6 | Feb 2, 2026 | |
| AXSM Axsome Therapeutics | Downgrades: Equal-Weight | $196 → $204 | $223.70 | -8.81% | 4 | Jan 8, 2026 | |
| CERT Certara | Maintains: Equal-Weight | $16 → $12 | $6.19 | +93.86% | 2 | Dec 18, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Overweight | $20 | $8.46 | +136.41% | 1 | Dec 5, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Overweight | $34 | $28.51 | +19.26% | 1 | Nov 21, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $90 → $115 | $67.64 | +70.02% | 3 | Oct 30, 2025 | |
| RMD ResMed | Maintains: Overweight | $298 → $304 | $209.43 | +45.16% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $383 | $297.14 | +28.90% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $3 → $1.5 | $2.51 | -40.24% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $67 | $64.57 | +3.76% | 1 | Feb 14, 2025 |
Generate Biomedicines
Mar 24, 2026
Initiates: Overweight
Price Target: $20
Current: $14.46
Upside: +38.31%
Eikon Therapeutics
Mar 2, 2026
Initiates: Overweight
Price Target: $32
Current: $10.27
Upside: +211.59%
BridgeBio Pharma
Feb 25, 2026
Maintains: Overweight
Price Target: $96 → $98
Current: $68.99
Upside: +42.05%
Exelixis
Feb 2, 2026
Maintains: Equal-Weight
Price Target: $48 → $49
Current: $44.17
Upside: +10.94%
Axsome Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $196 → $204
Current: $223.70
Upside: -8.81%
Certara
Dec 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $12
Current: $6.19
Upside: +93.86%
BridgeBio Oncology Therapeutics
Dec 5, 2025
Initiates: Overweight
Price Target: $20
Current: $8.46
Upside: +136.41%
MapLight Therapeutics
Nov 21, 2025
Initiates: Overweight
Price Target: $34
Current: $28.51
Upside: +19.26%
Disc Medicine
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $115
Current: $67.64
Upside: +70.02%
ResMed
Oct 21, 2025
Maintains: Overweight
Price Target: $298 → $304
Current: $209.43
Upside: +45.16%
Oct 20, 2025
Maintains: Overweight
Price Target: $350 → $383
Current: $297.14
Upside: +28.90%
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $2.51
Upside: -40.24%
Feb 14, 2025
Assumes: Overweight
Price Target: $67
Current: $64.57
Upside: +3.76%